OTCMKTS:ARGSQ Argos Therapeutics (ARGSQ) Stock Forecast, Price & News $0.05 0.00 (0.00%) (As of 10/10/2019) Add Compare Share Share Today's Range$0.05▼$0.0550-Day Range$0.05▼$0.0552-Week Range$0.02▼$0.25VolumeN/AAverage Volume13,394 shsMarket Capitalization$571,698.00P/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsInsider TradesHeadlinesSEC FilingsProfileChartCompetitorsFinancialsInsider TradesHeadlinesSEC Filings About Argos Therapeutics (OTCMKTS:ARGSQ) StockArgos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.Read More Receive ARGSQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Argos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARGSQ Stock News HeadlinesApril 9, 2023 | marketwatch.com2023-2029 mRNA Vaccines & Therapeutics Market Opportunities and ForecastApril 6, 2023 | marketwatch.commRNA Vaccines & Therapeutics Market Share and Forecast till 2031May 30, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.April 6, 2023 | americanbankingnews.comHead to Head Comparison: Argos Therapeutics (OTCMKTS:ARGSQ) & Angion Biomedica (NASDAQ:ANGN)March 21, 2023 | mirror.co.ukArgos, B&M, Iceland, Homesense and more all closing shops this month - see full listFebruary 25, 2023 | mirror.co.ukArgos to close more shops for good in Sainsbury's plan – see which branches are affectedSeptember 9, 2022 | dailymail.co.ukOutrage as Argos sells G-strings for childrenSeptember 8, 2022 | dailymail.co.ukArgosMay 30, 2023 | Edge On The Street (Ad)How to Invest in AI's Fast-Growing MarketThe AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.June 19, 2021 | investing.comArgos Therapeutics Inc (ARGSQ)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ARGSQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Argos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARGSQ Company Calendar Last Earnings8/09/2017Today5/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ARGSQ CUSIPN/A CIK1105533 Webwww.argostherapeutics.com Phone919-287-6300FaxN/AEmployees21Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.90 million Price / Sales0.30 Cash FlowN/A Price / Cash FlowN/A Book Value($1.63) per share Price / Book-0.03Miscellaneous Outstanding Shares10,587,000Free FloatN/AMarket Cap$571,698.00 OptionableNot Optionable Beta2.47 Key ExecutivesDr. Charles A. Nicolette (Age 57)Consultant Mr. Jeffrey D. Abbey (Age 57)Consultant & Director Dr. Richard D. Katz (Age 55)Consultant Ms. Lori R. Harrelson CPA (Age 50)CPA, VP of Fin. Mr. William N. WoffordSec.Key CompetitorsPeak PharmaceuticalsOTCMKTS:PKPHRespireRx PharmaceuticalsOTCMKTS:RSPIAmarantus BioScienceOTCMKTS:AMBSAmerican Bio MedicaOTCMKTS:ABMCChina SXT PharmaceuticalsNASDAQ:SXTCView All Competitors ARGSQ Stock - Frequently Asked Questions How have ARGSQ shares performed in 2023? Argos Therapeutics' stock was trading at $0.0540 at the beginning of the year. Since then, ARGSQ stock has increased by 0.0% and is now trading at $0.0540. View the best growth stocks for 2023 here. How were Argos Therapeutics' earnings last quarter? Argos Therapeutics Inc (OTCMKTS:ARGSQ) announced its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.50) by $0.30. The biopharmaceutical company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.10 million. When did Argos Therapeutics' stock split? Argos Therapeutics shares reverse split before market open on Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Argos Therapeutics' stock symbol? Argos Therapeutics trades on the OTCMKTS under the ticker symbol "ARGSQ." How do I buy shares of Argos Therapeutics? Shares of ARGSQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Argos Therapeutics' stock price today? One share of ARGSQ stock can currently be purchased for approximately $0.05. How much money does Argos Therapeutics make? Argos Therapeutics (OTCMKTS:ARGSQ) has a market capitalization of $571,698.00 and generates $1.90 million in revenue each year. How can I contact Argos Therapeutics? Argos Therapeutics' mailing address is 4233 TECHNOLOGY DR, DURHAM NC, 27704. The official website for the company is www.argostherapeutics.com. The biopharmaceutical company can be reached via phone at 919-287-6300. This page (OTCMKTS:ARGSQ) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Argos Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.